Page results
-
A pioneering breast cancer therapy developed by UCLH and UCL, which requires just one shot of radiotherapy rather than conventional weeks-long treatment, has proven to be as effective for most women in treating the disease.
-
How UCLH uses clinical data in research.
-
Doctors at UCLH and University College London (UCL) have developed a digital decision-making aid, MENO.pause, to help clinicians manage menopause symptoms in the best way for individual patients’ health conditions.
-
Initial results from an early phase study testing the safety and efficacy of a new drug for multiple myeloma have shown a 100 per cent overall response rate in patients with recurrent disease who were given the clinically recommended dose of the investigational drug.
-
This two-part workshop is specially created for teenagers seeking to understand their anxiety more deeply and discover practical, effective strategies to manage it.
-
Learn more about how UCLH celebrated Research Open Day this month.
-
Fears that people with high blood pressure are more at risk from severe Covid-19 because it is easier for the virus to enter their cells and tissues have been laid to rest, thanks to research involving UCLH.
-
Dr. Patrick Murphy is a principal clinical neuropsychologist at the National Hospital for Neurology and Neurosurgery
-
SUMMIT Study results on the benefits of large-scale screening for lung cancer are published in The Lancet Oncology today (26 March), ahead of the formal addition of lung cancer screening to the UK national screening programme from 1 April.
-
This page tells you about the procedure known as a Bronchial Artery Embolisation (BAE).
File results
-
FOI/2022/0172 - Contraceptive pill data
-
FOI/2022/0174 - Clinical systems for bed management, diagnostic reporting, discharge letters, and integration platform systems
-
FOI/2022/0177 - Assessment and treatment unit for mental health and learning disabilities
-
FOI/2022/0186 - Gender neutral toilets at the Trust
-
FOI/2022/0187 - Intra-operative cell salvage procedures
-
FOI/2022/0189 - Drug treatments for Revolade, Nplate, Doptelet, and Tavlesse
-
FOI/2022/0190 - Spend on private healthcare providers for staff
-
FOI/2022/0192 - Drug treatment for Melanoma patients
-
FOI/2022/0193 - Drug treatment for breast cancer
-
FOI/2022/0194 - Drug treatment for lung cancer